Oct 10 (Reuters) - Roche Holding AG's experimentaldrug gantenerumab and Eli Lilly & Co's solanezumab havebeen chosen to be tested in a high-profile global Alzheimer'sdisease prevention trial, and a second Lilly medicine is beingconsidered for potential inclusion in the study, WashingtonUniversity said on Wednesday.
The St. Louis-based University said the trial, expected tobegin in early 2013, will enroll 160 patients with inheritedgene mutations that typically lead to Alzheimer's disease at ayoung age.
(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick)
((firstname.lastname@example.org)(646 223 6030))
Keywords: ROCHE LILLY/ALZHEIMERS